Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California News Observer.
Press releases published on June 17, 2025
Habit Burger & Grill Reveals Hot Dads Cast for Summer Salad Calendar
GlobeNewswire
·
June 17, 2025
IRVINE, June 17, 2025 (GLOBE NEWSWIRE) -- After a nationwide search for America’s hottest dads, Habit Burger …
Next-Gen Edge AI Solutions for the Real World: Autonomous Navigation for Drones, Surveillance and Robotics
GlobeNewswire
·
June 17, 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions enabling Edge AI Intelligence, today announced its collaboration with Aerora, a provider of integrated NDAA-compliant …
Unicycive Therapeutics, Inc. Announces Reverse Stock Split
GlobeNewswire
·
June 17, 2025
LOS ALTOS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it will implement a 1-for-10 reverse split …
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
GlobeNewswire
·
June 17, 2025
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative diseases VTX3232 …
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
·
June 17, 2025
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was …
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
GlobeNewswire
·
June 17, 2025
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with complete response remained in complete response at ≥ 6 …
Point Surpasses 15,000 Homeowners Funded, Tapping into More Than $1.5 Billion in Home Equity
GlobeNewswire
·
June 17, 2025
Palo Alto, California, June 17, 2025 (GLOBE NEWSWIRE) -- Point, a leading home equity investment platform, proudly announces a significant milestone: funding its 15,000th homeowner. This achievement underscores Point's commitment to providing innovative …
DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
GlobeNewswire
·
June 17, 2025
LOS ANGELES, June 17, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed …
ChampionsGate Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on June 20, 2025
GlobeNewswire
·
June 17, 2025
Monterey, CA, June 16, 2025 (GLOBE NEWSWIRE) -- ChampionsGate Acquisition Corporation (the “Company”) (Nasdaq: CHPGU), a blank check company, today announced that, commencing on June 20, 2025, holders of the 7,475,000 units (the “Units”) sold in the …